It will explore how these molecules drive tumor growth, and suggests that targeting C3a and C5a alongside standard therapies like chemotherapy, radiotherapy, and immune-checkpoint inhibitors could enhance cancer treatment outcomes [15,16]. The gene discussed is C5; the disease is neoplasm.